SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending amid speculation around potential connections to Elon Musk's Grok AI. The community is also excited about the project's fundamentals, including its zero-tax setup, and a potential listing on Binance. Many participants are expressing bullish sentiment, using terms like "WAGMI" and "To The Moon".

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community celebrates its joke-inspired roots and long-term presence on the Solana blockchain. Many are drawn to its dedicated community, locked liquidity, and association with the popular "What's UpDog?" meme, while others highlight its potential within the broader meme coin landscape.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE.X is trending as the community rallies around the meme coin, expressing bullish sentiment and encouraging others to join before a potential surge. Talk centers on community growth, relentless promotion, and the expectation of significant gains. The coin's association with the popular "Rage Guy" meme and potential listing on major exchanges are also fueling excitement.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is trending as the community rallies around $UPDOG, a Solana-based meme coin exclusively listed on Jupiter's strict list, driving discussions about loading up on the token. The focus is on swapping $SOL for $UPDOG on Jupiter, with community members highlighting the project's long-term development and strong community vibes. Amidst the broader meme coin season, UpDog's unique listing on Jupiter is a key catalyst.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics ($CVKD) is trending as traders discuss its bullish technical setup and potential for an upside breakout, fueled by recent news of the acquisition of anti-coagulant assets. The community highlights the momentum and strong buyer confidence, while also noting the healthcare technology niche and upcoming milestones for their drug Tecarfarin. Some are watching for volume to confirm the move, and analysts are noting high price targets for the stock.

Codatta

Codatta ($XNY.X) is trending amid discussions about its on-chain fingerprint verification launch and potential applications of its AI/data utility. The community is analyzing its chart patterns, with some pointing to bullish setups and expecting new highs, while others are watching key support levels for potential entry points. Sentiment is mixed, with some expressing excitement about its potential and others remaining cautious.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals ($ENTA) is trending due to topline results from its Phase 2b study, with community members eagerly awaiting further details. Some speculate on the potential for significant gains depending on the results, especially related to viral load reduction. The company's work on zelicapavir, an oral RSV N-protein inhibitor, is also drawing attention, particularly its potential in the adult RSV therapeutics market.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive (DRV.X) is trending as the community discusses its strong chart and potential for another leg up, with some highlighting treasury loop mechanisms like airdrops and buybacks. The community also notes ongoing consolidation and recent upward movement, with some suggesting potential buybacks are underway. Furthermore, the community is discussing the partnership of Synthetix and Derive to build derivatives on ETH L1.

The address GaPbGp23pPuY9QBLPUjUEBn2MKEroTe9Q3M3f2Xpump corresponds to a token on the Solana blockchain, specifically an SPL (Solana Program Library) token. This address is likely the mint address for a specific token, which is used to identify the token on the Solana network. Based on the context and available information, this token appears to be associated with the pump.fun platform, as the address ends with "pump," which is a common identifier for tokens created via this platform. GaPbGp23pPuY9QBLPUjUEBn2MKEroTe9Q3M3f2Xpump is the mint address of an SPL token on the Solana blockchain. The mint address is a unique identifier for a token, storing metadata like total supply and mint authority. The "pump" in the address strongly suggests it was created on solanapump (commonly known as pump.fun), a popular Solana-based platform for launching meme coins and other tokens. Pump.fun allows users to create and trade tokens easily, often with a focus on community-driven or speculative projects like memecoins.

Shitcoin

$SHITCOIN.X is gaining traction as discussions around meme coins and Solana-based tokens intensify, with many comparing it to previous successes like $FARTCOIN.X. The community is actively sharing links and seeking information on where to purchase the token, with some expressing optimism about its potential while others remain skeptical. Mentions of the Phantom wallet suggest interest in tracking and managing the token within that ecosystem.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

BOB.X is trending as holders celebrate its growing community and compare it to other cryptocurrencies. Community members are discussing its capped supply and upcoming halving event, drawing comparisons to Bitcoin and its potential within the ICP ecosystem. Some users are also pointing to the potential for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vor Bio (VOR) announced on Wednesday that its collaborator, RemeGen Co., achieved the primary goal in a late-stage study in China evaluating Telitacicept in adults with primary Sjögren's disease.Shares of <a href="https://stocktwits.com/symbol/VOR">VOR</a> jumped 19% in morning trade at the time of writing. On Stocktwits, retail sentiment around Vor Bio jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_10_23_25_AM_png_ff26de0d0d.webp" alt="VOR's Sentiment Meter and Message Volume as of 10:23 a.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="628" height="64"><figcaption>VOR's Sentiment Meter and Message Volume as of 10:23 a.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Vor, highlighting its ongoing trials and funding availability.<stembedurl>https://stocktwits.com/StockGuru95/message/624945818</stembedurl>Another said they are eyeing a breakout for the stock.<stembedurl>https://stocktwits.com/StockGuru95/message/624929413</stembedurl>The late-stage clinical study in China achieved the primary endpoint of improving disease activity measured by a reduction in EULAR Sjögren's syndrome disease activity index (ESSDAI), compared to placebo, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.vorbio.com/news-releases/news-release-details/telitacicept-achieved-primary-endpoint-phase-3-clinical-study">said</a>. Telitacicept also demonstrated a favorable safety profile in the study, it added.RemeGen now plans to submit a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for primary Sjögren’s disease. If approved, primary Sjögren’s disease will become Telitacicept’s fourth approved indication in China after systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG), Vor Bio noted.Sjögren’s disease is a chronic autoimmune condition in which overactive B cells drive inflammation, damaging moisture-producing glands and, in many cases, other organs. Symptoms include dry eyes and dry mouth, alongside fatigue, pain, and systemic complications affecting the skin, lungs, kidneys, and nervous system.“Sjögren’s represents a significant global expansion opportunity for Vor beyond myasthenia gravis, further extending the reach and impact of our portfolio,” said Vor Bio CEO Jean-Paul Kress.Vor Bio and Remegen entered into an exclusive license agreement granting Vor Bio the global rights to develop and commercialize Telitacicept, excluding China, Hong Kong, Macau, and Taiwan, in June. On Wednesday, the company said that it is evaluating the timing of a global late-stage study of the drug in primary Sjögren's disease.VOR stock is up by 78% this year and by 138% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/virtuals-turns-agents-into-a-team/chrCLP7Rd9L">Virtuals Turns Agents Into A Team</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening

A late-stage clinical study in China conducted by Vor Bio’s collaborator RemeGen Co., which is evaluating Telitacicept in adults with primary Sjögren's disease, achieved the primary endpoint of improving disease activity compared to placebo.

Vor Bio Stock Jumped 24% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening

Equity

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.

Vor Biopharma Secures $55.6M for Cancer Therapy Trials

Vor Biopharma Secures $55.6M for Cancer Therapy Trials...

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that...

Vor Biopharma (VOR) Receives a Buy from Barclays

Barclays analyst Carter Gould maintained a Buy rating on Vor Biopharma (VOR Research Report) today and set a price target of $3.00. The company's...

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...

Vor Biopharma GAAP EPS of -$0.39 beats by $0.11

Vor Biopharma GAAP EPS of -$0.39 beats by $0.11...

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results  and Provides Company Update

Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the...

CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

VOR
Vor Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VOR News

VOR Vor Biopharma Inc